Pediatric patients with immune-mediated diseases on immunosuppressants have low risk of severe COVID-19 and no increase in flare rate after SARS CoV-2 exposure.

J Infect

Department of Clinical Immunology, National Institute for Mother and Child Health Alessandrescu-Rusescu, Lacul Tei Boulevard, 120, Bucharest, Romania. Electronic address:

Published: September 2022

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212399	PMC
http://dx.doi.org/10.1016/j.jinf.2022.06.012	DOI Listing

Publication Analysis

pediatric patients

patients immune-mediated

immune-mediated diseases

diseases immunosuppressants

immunosuppressants low

low risk

risk severe

severe covid-19

covid-19 increase

increase flare

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!